SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4597-4605. Prepublished online as a Blood First Edition Paper on March 2, 2006; DOI 10.1182/blood-2005-08-3207. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: 2005-08-3207v1 107/12/4597    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schiavo, R. Articles by Biragyn, A. Search for Related Content PubMed PubMed Citation Articles by Schiavo, R. Articles by Biragyn, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 9, 2005 Accepted February 14, 2006 Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T cell responses Roberta Schiavo, Dolgor Baatar, Purevdorj Olkhanud, Fred E Indig, Nicholas Restifo, Dennis Taub, and Arya Biragyn* Laboratory of Immunology, Gerontology Research Center, National Institute on Aging, Baltimore, MD, USA Research Resources Branch, National Institue on Aging, NIH, Baltimore, MD, USA Surgery Branch, National Cancer Institute, Bethesda, MD, USA * Corresponding author; email: biragyna{at}mail.nih.gov. Chemokines are key controllers of cell trafficking and are involved in numerous pathological and inflammatory conditions. However, the fate of a chemokine ligand, once it is endocytosed with its receptor, remains obscure. Here, using chemokine-tumor antigen fusion constructs, we demonstrate for the first time that chemokines are internalized to early/late endosomal and lysosomal compartments through a clathrin-dependent process and subsequently delivered to the cytosol for proteasomal processing, facilitating efficient cross-presentation to the TAP-1-dependent MHC class I processing pathway. These data not only elucidate the intracellular fate of chemokine ligands upon receptor uptake, but also demonstrate the superior carrier potency of chemokines for delivering self-antigens to both Class I and II processing pathways to induce CD8+ and CD4+ T cell responses. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Mukai, Y. Maeda, T. Tamura, M. Matsuoka, Y. Tsukamoto, and M. Makino Induction of Cross-Priming of Naive CD8+ T Lymphocytes by Recombinant Bacillus Calmette-Guerin That Secretes Heat Shock Protein 70-Major Membrane Protein-II Fusion Protein J. Immunol., November 15, 2009; 183(10): 6561 - 6568. [Abstract] [Full Text] [PDF] H. Qin, S.-c. Cha, S. S. Neelapu, Y. Lou, J. Wei, Y.-J. Liu, and L. W. Kwak Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity Blood, November 5, 2009; 114(19): 4142 - 4149. [Abstract] [Full Text] [PDF] G. Almanzar, P. B. Olkhanud, M. Bodogai, C. Dell'Agnola, D. Baatar, S. M. Hewitt, C. Ghimenton, M. K. Tummala, A. T. Weeraratna, K. S. Hoek, et al. Sperm-Derived SPANX-B Is a Clinically Relevant Tumor Antigen That Is Expressed in Human Tumors and Readily Recognized by Human CD4+ and CD8+ T Cells Clin. Cancer Res., March 15, 2009; 15(6): 1954 - 1963. [Abstract] [Full Text] [PDF] S. K. Dissanayake, P. B. Olkhanud, M. P. O'Connell, A. Carter, A. D. French, T. C. Camilli, C. D. Emeche, K. J. Hewitt, D. T. Rosenthal, P. D. Leotlela, et al. Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation Cancer Res., December 15, 2008; 68(24): 10205 - 10214. [Abstract] [Full Text] [PDF] E. Tagliani, P. Guermonprez, J. Sepulveda, M. Lopez-Bravo, C. Ardavin, S. Amigorena, F. Benvenuti, and O. R. Burrone Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8{alpha}+ Dendritic Cells J. Immunol., March 1, 2008; 180(5): 3201 - 3209. [Abstract] [Full Text] [PDF] Y.-s. Wang, G.-q. Wang, Y.-j. Wen, L. Wang, X.-c. Chen, P. Chen, B. Kan, J. Li, C. Huang, Y. Lu, et al. Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1 Clin. Cancer Res., November 15, 2007; 13(22): 6779 - 6787. [Abstract] [Full Text] [PDF] A. B. Fredriksen and B. Bogen Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences Blood, September 15, 2007; 110(6): 1797 - 1805. [Abstract] [Full Text] [PDF] O. Adotevi, B. Vingert, L. Freyburger, P. Shrikant, Y.-C. Lone, F. Quintin-Colonna, N. Haicheur, M. Amessou, A. Herbelin, P. Langlade-Demoyen, et al. B Subunit of Shiga Toxin-Based Vaccines Synergize with {alpha}-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity J. Immunol., September 1, 2007; 179(5): 3371 - 3379. [Abstract] [Full Text] [PDF] D. Baatar, P. Olkhanud, D. Newton, K. Sumitomo, and A. Biragyn CCR4-Expressing T Cell Tumors Can Be Specifically Controlled via Delivery of Toxins to Chemokine Receptors J. Immunol., August 1, 2007; 179(3): 1996 - 2004. [Abstract] [Full Text] [PDF] A. Biragyn, R. Schiavo, P. Olkhanud, K. Sumitomo, A. King, M. McCain, F. E. Indig, G. Almanzar, and D. Baatar Tumor-Associated Embryonic Antigen-Expressing Vaccines that Target CCR6 Elicit Potent CD8+ T Cell-Mediated Protective and Therapeutic Antitumor Immunity J. Immunol., July 15, 2007; 179(2): 1381 - 1388. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020